Silvercrest Asset Management Group LLC lifted its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 21.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,953,806 shares of the company's stock after acquiring an additional 350,970 shares during the quarter. Silvercrest Asset Management Group LLC owned 4.66% of SI-BONE worth $27,392,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of SI-BONE by 14.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company's stock valued at $2,486,000 after buying an additional 22,732 shares during the last quarter. Rhumbline Advisers grew its position in shares of SI-BONE by 3.0% in the 4th quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after buying an additional 1,683 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of SI-BONE by 17.6% in the 4th quarter. MetLife Investment Management LLC now owns 27,421 shares of the company's stock valued at $384,000 after buying an additional 4,104 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in shares of SI-BONE in the 4th quarter valued at $155,000. Finally, VELA Investment Management LLC grew its position in shares of SI-BONE by 23.8% in the 4th quarter. VELA Investment Management LLC now owns 122,671 shares of the company's stock valued at $1,720,000 after buying an additional 23,592 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial raised their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th.
Read Our Latest Stock Analysis on SIBN
SI-BONE Stock Performance
Shares of SIBN stock traded up $0.26 during mid-day trading on Tuesday, hitting $19.71. The stock had a trading volume of 300,623 shares, compared to its average volume of 375,093. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The firm has a market cap of $839.94 million, a PE ratio of -21.42 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The company's 50-day simple moving average is $14.92 and its 200-day simple moving average is $15.08.
SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. Sell-side analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
Insiders Place Their Bets
In related news, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. This represents a 1.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Laura Francis sold 38,504 shares of the business's stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total value of $661,498.72. Following the sale, the chief executive officer now owns 302,958 shares in the company, valued at approximately $5,204,818.44. The trade was a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,153 shares of company stock worth $935,040. 4.00% of the stock is owned by company insiders.
SI-BONE Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Further Reading
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
